posted on Nov, 28 2021 @ 11:40 PM
Here are a few cases.
Case 1 was a 61-year-old woman with no significant history. She was found dead at home by her husband 3 days after receiving the first shot of
tozinameran, with no episode reported in the intervening time. A spinal tap revealed bloody cerebrospinal fluid. Neither autopsy nor postmortem
imaging study was performed.
Case 2 was a 26-year-old woman with no underlying conditions. After the first shot of tozinameran, her subsequent course was unremarkable until she
was found dead 4 days later at home. Postmortem imaging revealed a hematoma 3.5 cm in diameter at the left cerebellopontine angle compressing the
brainstem and secondary subarachnoid hemorrhage.
Case 3 was a 72-year-old woman with hepatitis C and dyslipidemia. Three days after the first shot of tozinameran, she developed dysarthria with
complaints of headache and nausea. Brain imaging revealed a large hematoma with ventricular rupture. Her platelet count was 216,000/mm3. She died 5
days after receiving tozinameran.
Case 4 was a 69-year-old woman. No underlying condition was specified. She had been well until she was found dead at home 9 days after the first shot
of tozinameran. An autopsy revealed that she died of ICH. No other information was available.
Further studies are underway.
Reports of cerebral venous sinus thrombosis and intracranial hemorrhage (ICH) following the administration of coronavirus vaccines have raised
concerns regarding their safety. Although no regulatory authority has recognized ICH as an adverse event associated with tozinameran (BNT162b2,
Pfizer-BioNTech), fatal and non-fatal cases have been reported. In Japan, 10 fatal cases (five men and women) have been reported to date. Four of the
five women died of ICH and the other died of aspiration pneumonia, whereas all five men died of causes other than stroke. This imbalance is
incompatible with the mortality data on cardiovascular diseases in the National Statistics, which show no apparent disparity between sexes or between
hemorrhagic and ischemic stroke. Cumulatively, our analysis reveals a disproportionately high incidence of death by ICH in Japanese women who received
tozinameran, suggesting a potential association of ICH with the vaccine. Although we understand that the benefits of tozinameran still outweigh the
risks, we believe that a causal link with the vaccine is not proven but possible and warrants further analysis.